Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day. World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. In an effort to drive awareness and […]
Medtronic
Medtronic brings Blue Balloon Challenge to World Diabetes Day
To mark World Diabetes Day and National Diabetes Month in the U.S., Medtronic (NYSE:MDT) is bringing back its “Blue Balloon Challenge.” Introduced in 2021, the movement encourages people with diabetes to help drive awareness and understanding of the chronic condition. The company instructs people to take a video or photo while bouncing a blue balloon […]
NICE recommends automated insulin delivery tech rollout in UK, Medtronic, Dexcom applaud
An independent committee of the National Institute for Health and Care Excellence (NICE) voiced support for closed-loop insulin delivery. The UK-based institute recommended offering automated insulin delivery (AID) for people whose type 1 diabetes is not controlled with their current device despite best possible management with an insulin pump or real-time or intermittently scanned continuous […]
How the new Medtronic CGM-insulin pen combo simplifies diabetes management
Medtronic (NYSE:MDT) named its next-generation “Simplera” continuous glucose monitor (CGM) as a nod to its simplicity. The company, which just initiated the system’s launch in Europe following CE mark approval, is exceedingly optimistic about the technology. Medtronic’s all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Its […]
FDA approves next-gen intrathecal drug delivery system from Medtronic
Medtronic (NYSE:MDT) announced today that the FDA approved its next-generation SynchroMed III intrathecal drug delivery system. The medtech giant designed SynchroMed III to treat patients with chronic pain, cancer pain and severe spasticity. The targeted drug delivery (TDD) system alleviates symptoms by delivering medication directly to the fluid surrounding the spinal cord. SynchroMed III builds upon […]
Medtronic warns on previous software MiniMed 780G in Germany
Medtronic (NYSE:MDT) issued an urgent field safety notice in Germany to warn of a potential issue with its MiniMed 780G system. MiniMed 780G, Medtronic’s next-generation automated insulin delivery system, has been available in Europe since earning CE mark in mid-2020. In March 2021, the company first communicated that its pumps with software version 6.5 could […]
New data shows consistency of Medtronic MiniMed 780G in different demos, cultures
Medtronic (NYSE:MDT) today announced real-world data demonstrating the global consistency of its MiniMed 780G automated insulin delivery system. The data, according to Medtronic, demonstrates that using the system allows people with diabetes to meet or exceed internationally recommended targets regardless of location. The medtech giant says a barrier to automated insulin delivery (AID) adoption and […]
Medtronic wins CE mark for next-gen Simplera CGM with InPen integration
Medtronic (NYSE:MDT) announced today that it received CE mark approval for its new Simplera continuous glucose monitor (CGM). The all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Medtronic’s newest no-fingerstick sensor eliminates the need for overtape, too. It seamlessly integrates with the InPen smart insulin […]
Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs
Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry. The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to […]
Lawsuit alleges ‘potentially problematic’ patient data sharing from Medtronic Diabetes devices
A class-action lawsuit filed against Medtronic (NYSE:MDT) alleges that the company’s insulin delivery devices shared patient data with third parties. The lawsuit — filed by the plaintiff “A.H.” in U.S. District Court in Central California — levels allegations against Medtronic and its MiniMed and InPen devices. It addresses MiniMed’s transmission and disclosure of personally identifiable information […]